Summary of Key Information:
Reporting Period: Fourth quarter and financial year ended March 31, 2026
Nature of Filing / Announcement: Outcome of Board Meeting under Regulation 30 of SEBI Listing Regulations
Audit Opinion:
Unmodified Opinion issued by M/s. BSR & Co. LLP, Statutory Auditors
Key Financial Highlights [₹ in lakhs]:
Standalone Results:
Year Ended March 31, 2026:
- Revenue from Operations: ₹1,05,507.10
- Total Income: ₹1,10,780.10
- Net Profit: ₹26,326.60
- EPS: ₹25.10
Year Ended March 31, 2025 (Comparative):
- Revenue from Operations: ₹1,20,008.60
- Total Income: ₹1,24,453.30
- Net Profit: ₹37,296.40
- EPS: ₹35.60
Quarter Ended March 31, 2026:
- Revenue from Operations: ₹32,589.20
- Total Income: ₹34,143.70
- Net Profit: ₹9,002.20
Quarter Ended December 31, 2025 (Unaudited):
- Revenue from Operations: ₹27,813.30
- Total Income: ₹28,821.60
- Net Profit: ₹6,778.00
Consolidated Results:
Year Ended March 31, 2026:
- Revenue from Operations: ₹1,05,489.07
- Total Income: ₹1,10,724.60
- Net Profit attributable to owners: ₹26,009.00
- EPS: ₹24.78
Year Ended March 31, 2025 (Comparative):
- Revenue from Operations: ₹1,20,008.69
- Total Income: ₹1,24,453.36
- Net Profit attributable to owners: ₹37,164.23
- EPS: ₹35.52
Quarter Ended March 31, 2026:
- Revenue from Operations: ₹32,607.96
- Total Income: ₹34,142.90
- Net Profit attributable to owners: ₹8,879.05
Quarter Ended December 31, 2025 (Unaudited):
- Revenue from Operations: ₹21,170.60
- Total Income: ₹28,774.22
- Net Profit attributable to owners: ₹6,364.15
Segment-wise Performance:
The entire business is considered as a single operating segment (Pharmaceutical products) under Ind AS 108.
Corporate Actions:
- Dividend: Recommended final dividend of ₹7.55 per equity share (face value ₹1 each) for FY 2025-26
- Record Date: July 24, 2026
- Subject to shareholder approval at ensuing AGM
Auditor Appointments:
- Internal Auditor for FY27: M/s. Manubhai & Shah LLP
- Cost Auditor for FY27: M/s. Dalwadi & Associates
- Both firms declared not related to any directors
Director Appointment:
- Mrs. Ekta Gupta appointed as Additional Independent Director effective June 1, 2026 for 5 years
- Subject to shareholder approval
- Profile: MBA in Finance from Cardiff University, B.Com (Hons) from Lady Shri Ram College
- Current Director at Sanghi Polymers Private Limited
- Previous experience with Deutsche Bank and Financial Markets
- No shareholding in company
Other Disclosures:
- No deviation or variation in proceeds of public issues
- No outstanding defaults on loans and debt securities
- Unmodified audit opinion on both standalone and consolidated results
Other Significant Information:
Exceptional Item:
- Recognized ₹327.54 lakh exceptional item towards employee benefit obligation
- Arises from revised definition of wages under New Labour Codes notified November 21, 2025
- Considered regulatory-driven and non-recurring [Non-Recurring]
Acquisition:
- Celliimune Biotech Private Limited incorporated January 15, 2025
- Acquired by Concord Biotech Limited on April 2, 2026
- Investment of ₹1.2 lakhs made as of March 31, 2026 out of total consideration ₹66 lakhs
- Became wholly owned subsidiary on April 2, 2026
Subsidiaries and Joint Venture included in consolidation:
- Concord Lifegen Limited (wholly owned subsidiary, w.e.f July 21, 2025)
- Stellon Biotech Inc. (subsidiary, w.e.f July 1, 2025)
- Concord Biotech Japan K.K. (joint venture)
Entities:
- Statutory Auditor: M/s. BSR & Co. LLP
- Internal Auditor: M/s. Manubhai & Shah LLP (Firm Registration No. 106041W)
- Cost Auditor: M/s. Dalwadi & Associates (Firm Registration No. 000338)